Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Amortization of Deferred Charges: 2019-2025

Historic Amortization of Deferred Charges for Benitec Biopharma (BNTC) over the last 5 years, with Jun 2025 value amounting to $104,000.

  • Benitec Biopharma's Amortization of Deferred Charges rose 60.00% to $104,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $330,000, marking a year-over-year increase of 28.91%. This contributed to the annual value of $330,000 for FY2025, which is 28.91% up from last year.
  • Per Benitec Biopharma's latest filing, its Amortization of Deferred Charges stood at $104,000 for Q2 2025, which was up 11.83% from $93,000 recorded in Q1 2025.
  • In the past 5 years, Benitec Biopharma's Amortization of Deferred Charges registered a high of $104,000 during Q2 2025, and its lowest value of $48,000 during Q1 2021.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $65,000 (2024), whereas its average is $71,000.
  • Data for Benitec Biopharma's Amortization of Deferred Charges shows a peak YoY skyrocketed of 60.00% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Benitec Biopharma's Amortization of Deferred Charges stood at $58,000 in 2021, then climbed by 5.17% to $61,000 in 2022, then grew by 3.28% to $63,000 in 2023, then grew by 6.35% to $67,000 in 2024, then skyrocketed by 60.00% to $104,000 in 2025.
  • Its last three reported values are $104,000 in Q2 2025, $93,000 for Q1 2025, and $67,000 during Q4 2024.